Speaker：Prof. Moustapha Hassan, Karolinska Institutet / Karolinska University Hospital

Abstract：Stem cell transplantation (SCT) is a curative treatment for patients suffering from hematological malignancies, solid tumors or genetic disorders. However, the clinical outcome is still far from satisfactory due to severe complications following SCT. We strive to enhance SCT outcomes by addressing key complications such as graft failure, organ toxicity, and graft-versus-host disease (GVHD). Our approach includes personalized chemotherapy based on patient’s genotype in combination with pharmacokinetic/ pharmacodynamic (PK/PD) profile. In addition, we use preclinical models to study GVHD and cardiovascular toxicity aiming to improve the prophylactic treatment. Moreover, we are investigating the application of nanoparticles in theranostics for drug delivery and monitoring the treatment efficacy. By integrating these approaches, we aim to optimize SCT procedure and improve the clinical outcome.

Biography: Moustapha Hassan is currently Professor of Transplantation Research at the Karolinska Institutet, Sweden. His research focuses on personalized medicine, nanomedicine/theranostics and transplantation related complications. He is the inventor of liposomal busulfan. He is in the key coordinator position in EU and Sweden in pharmacological guided personalized treatment of conditioning regimen in connection with bone marrow transplantation since 1990s.